Pivotal Study In Subjects Undergoing A Transforaminal Lumbar Interbody Fusion
A Prospective, Randomized, Controlled, Blinded Study In Subjects Undergoing A Transforaminal Lumbar Interbody Fusion (TLIF) At One Or Two Levels Using Infuse™ Bone Graft and with an Intervertebral Body Fusion Device and Posterior Supplemental Fixation For The Treatment Of Symptomatic Degenerative Disease Of The Lumbosacral Spine
-
Clinical Trial Information
Trial Contact: Carlo, Charlene S; Monserrate, Francheska
Trial Phone: 321.841.1324 ; 321-841-4717
-
IRB No: 20.007.01
Protocol Abbrev: TLIF
Principal Investigator: Virgilio Matheus, MD, FACS
Phase: Device: Category B
Age Group: Adult
Secondary Protocol No: MDT17074SD1706
Treatment: Transforaminal Lumbar Interbody Fusion (TLIF) with Infuse will be used as treatment for symptomatic degenerative disease of the lumbosacral spine at one or two adjacent lumbar levels from L2-S1.
Therapies Involved: Surgery
ClinicalTrials.gov ID: NCT04073563
-
Objective
Evaluate the safety and effectiveness of the investigational treatment (Infuse) as compared to control group and to obtain approval for Infuse to be used in level one and two TLIF procedures.
-
Key Eligibility
Subject must have degenerative disease of the lumbosacral spine in one or two adjacent levels (L2 to S1) that results in radiculopathy secondary to nerve root compression.
